Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Healthtrust
Julphar
AstraZeneca
Farmers Insurance
McKesson
Harvard Business School
Teva
Dow

Generated: July 16, 2018

DrugPatentWatch Database Preview

TECHNIVIE Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Technivie patents expire, and when can generic versions of Technivie launch?

Technivie is a drug marketed by Abbvie Inc and is included in one NDA. There are ten patents protecting this drug.

This drug has three hundred and sixty patent family members in forty-five countries.

The generic ingredient in TECHNIVIE is ombitasvir; paritaprevir; ritonavir. One supplier is listed for this compound. Additional details are available on the ombitasvir; paritaprevir; ritonavir profile page.
Drug patent expirations by year for TECHNIVIE
Generic Entry Opportunity Date for TECHNIVIE
Generic Entry Date for TECHNIVIE*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage::
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for TECHNIVIE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie Inc TECHNIVIE ombitasvir; paritaprevir; ritonavir TABLET;ORAL 207931-001 Jul 24, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Abbvie Inc TECHNIVIE ombitasvir; paritaprevir; ritonavir TABLET;ORAL 207931-001 Jul 24, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Abbvie Inc TECHNIVIE ombitasvir; paritaprevir; ritonavir TABLET;ORAL 207931-001 Jul 24, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Abbvie Inc TECHNIVIE ombitasvir; paritaprevir; ritonavir TABLET;ORAL 207931-001 Jul 24, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for TECHNIVIE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie Inc TECHNIVIE ombitasvir; paritaprevir; ritonavir TABLET;ORAL 207931-001 Jul 24, 2015 ➤ Try a Free Trial ➤ Try a Free Trial
Abbvie Inc TECHNIVIE ombitasvir; paritaprevir; ritonavir TABLET;ORAL 207931-001 Jul 24, 2015 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for TECHNIVIE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,676,797 Anti-viral compounds ➤ Try a Free Trial
8,674,112 Polymorph of a pharmaceutical ➤ Try a Free Trial
8,716,454 Solid compositions ➤ Try a Free Trial
9,255,092 Polymorph of a pharmaceutical ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for TECHNIVIE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2015011 Lithuania ➤ Try a Free Trial PRODUCT NAME: PARITAPREVIRUM; REGISTRATION NO/DATE: EU/1/14.982 20150115
2015000042 Germany ➤ Try a Free Trial PRODUCT NAME: PARITAPREVIR; REGISTRATION NO/DATE: EU/1/14/982 20150115
7 50010-2015 Slovakia ➤ Try a Free Trial PRODUCT NAME: OMBITASVIR; REGISTRATION NO/DATE: EU/1/14/982/001 20150119
0150019 00156 Estonia ➤ Try a Free Trial PRODUCT NAME: PARITAPREVIIR;REG NO/DATE: EU/1/14/982 19.01.2015
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Dow
Queensland Health
QuintilesIMS
Covington
McKinsey
Federal Trade Commission
Accenture
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.